SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind Swift Labs trades jubilantly on Piramal stake buy buzz

04 Sep 2012 Evaluate

Ind-Swift Laboratories is currently trading at Rs. 57.90, up by 6.65 points or 12.98% from its previous closing of Rs. 51.25 on the BSE.

The scrip opened at Rs. 53.55 and has touched a high and low of Rs. 59.40 and Rs. 53.10 respectively. So far 939496 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 133.00 on 08-Feb-2012 and a 52 week low of Rs. 39.10 on 14-Aug-2012.

Last one week high and low of the scrip stood at Rs. 59.40 and Rs. 42.70 respectively. The current market cap of the company is Rs. 224.63 crore.

The promoters holding in the company stood at 50.58% while Institutions and Non-Institutions held 4.37% and 44.99% respectively.

Piramal Enterprise is looking to acquire Ind-Swift Laboratories’ contract research and manufacturing business, for a deal which is estimated to the worth of around Rs 1,000-1,200 crore. This acquisition is expected to boost the contract research and manufacturing services (CRAMS) division of Piramal, namely, Pharma Solutions along with its API manufacturing business.

In a bid to diversify into various businesses, Piramal after selling its domestic formulation business to Abbott for Rs 17,600 crore in 2010 has invested into pharma, telecom and information management and financial services sectors.

Meanwhile, Ind-Swift, a north India based pharmaceutical company, is the flagship company of India based Ind Swift Group. Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift Lab. Share Price

132.00 -13.30 (-9.15%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×